Healthcare
Live Price
Offline$293.17
-0.30% today
Window Change
-7.91%
Window
May 29, 2026 โ Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 15 bars ยท May 29, 2026 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Alnylam Pharmaceuticals, Inc. (ALNY) is a Healthcare stock with a market cap of $39.75B. The stock last traded around $293.17 and down 7.9% across the available one-year price window (May 29, 2026 โ Jun 18, 2026). Baseline metrics include revenue growth of +65.2%, EPS growth of +209.6%, a dividend yield of 0.0%. What stands out right now is revenue +65.2%, EPS +209.6%, free cash flow +1192.7% with operating margin 17.5% and ROIC 19.7%. Valuation already assumes a fairly strong business story at P/E 68.6 and price/sales 9.3. Stock Foundry combines ALNY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
Relative Read
ALNY is 6.62 pts behind over the shared 1Y window.
ALNY had 0.72 pts shallower max drawdown than SPY.
ALNY beat SPY in 0 of 1 calendar years shown and trailed in 1.
ALNY
-7.91%
Normalized return
SPY
-1.29%
S&P 500
Excess Return
-6.62 pts
Relative to SPY
ALNY Max Drawdown
-8.41%
Trailing 1Y
SPY Max Drawdown
-9.13%
Trailing 1Y
Uses the longest available daily history for ALNY and SPY.
| Year | ALNY | SPY | Excess | Leader |
|---|---|---|---|---|
| 2026 | -7.91% | +6.71% | -14.62 pts | SPY |
| 2025 | โ | +11.19% | -- | -- |
Powered by FMP stock_dividend. Includes historical ex-dates, pay dates, and payout amounts.
Dividend Yield
No active yield
Trailing 12M Payout
$0.00
Last Payout
โ
Next Step
Dividend yield means more when it is matched with payout durability, earnings quality, and sector context.